Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.
| MER Indicator |
MER description |
Target Fiscal Year |
Target |
| CARE_CURR |
Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load |
2016 |
4,547 |
| CARE_NEW |
Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load |
2016 |
833 |
| HTS_TST |
Number of individuals who received T&C services for HIV and received their test results during the past 12 months |
2016 |
11,842 |
| LAB_CAP |
By clinical laboratories |
2016 |
3 |
| LAB_CAP |
Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests |
2016 |
4 |
| PMTCT_ARV |
Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry) |
2016 |
105 |
| PMTCT_ARV |
Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery |
2016 |
105 |
| PMTCT_ARV |
Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy |
2016 |
19 |
| PMTCT_ARV |
Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy |
2016 |
86 |
| PMTCT_ARV |
Sum of New and Current disaggregates |
2016 |
105 |
| PMTCT_CTX |
Number of infants born to HIV-infected women who were started on cotrimoxizole (CTX) prophylaxis within 2 months of birth within the reporting period |
2016 |
103 |
| PMTCT_EID |
By infants who received a virologic test within 2 months of birth |
2016 |
68 |
| PMTCT_EID |
By infants who received their first virologic HIV test between 2 and 12 months of age |
2016 |
24 |
| PMTCT_EID |
Number of infants who had a virologic HIV test within 12 months of birth during the reporting period |
2016 |
92 |
| PMTCT_EID |
Sum of Infant Age disaggregates |
2016 |
92 |
| PMTCT_STAT |
By: Known positives at entry |
2016 |
19 |
| PMTCT_STAT |
By: Number of new positives identified |
2016 |
86 |
| PMTCT_STAT |
Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) |
2016 |
2,014 |
| PMTCT_STAT |
Sum of Positives Status disaggregates |
2016 |
105 |
| TB_IPT |
Age: 10-14 |
2016 |
2 |
| TB_IPT |
Age: 15-19 |
2016 |
28 |
| TB_IPT |
Sum of Age disaggregates |
2016 |
247 |
| TB_IPT |
The number of PLHIV newly enrolled in HIV care who start IPT during the reporting period |
2016 |
247 |
| TB_SCREEN |
Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load |
2016 |
4,547 |
| TB_SCREEN |
The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period |
2016 |
4,320 |
| TX_CURR |
Number of adults and children receiving antiretroviral therapy (ART) |
2016 |
4,241 |
| TX_NEW |
Number of adults and children newly enrolled on antiretroviral therapy (ART) |
2016 |
791 |
